Dupilumab Therapy for EGIDs
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-18
SponsorChildren's Hospital of Fudan University
About this trial
This is a single-center observational study to investigate the efficacy and tolerability of dupilumab in children with refractory eosinophilic gastrointestinal disorders.
Eligibility criteria
Qualifiers
Clinical diagnosis of Refractory Peptic Ulcers
with Refractory Eosinophilic Gastrointestinal Disorders
Disqualifiers
with Active Helicobacter pylori infection at present.
with Inflammatory bowel disease
with Parasite infection
with Cancer
Trial design
Treatments tested in this trial
- Dupilumab - Standard Dose
- subcutaneous injection
Treatment groups
20 Participants
are divided into 1 treatment groupLocations
1201102 Shanghai China
Sponsors and collaborators
Children's Hospital of Fudan University
Lead sponsor
Source ClinicalTrials.gov